Patra Krushna C, Bardeesy Nabeel, Mizukami Yusuke
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan.
Clin Transl Gastroenterol. 2017 Apr 6;8(4):e86. doi: 10.1038/ctg.2017.3.
Pancreatic ductal adenocarcinoma (PDA), one of the most lethal cancers worldwide, is associated with two main types of morphologically distinct precursors-pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). Although the progression of PanIN into invasive cancer has been well characterized, there remains an urgent need to understand the biology of IPMNs, which are larger radiographically detectable cystic tumors. IPMNs comprise a number of subtypes with heterogeneous histopathologic and clinical features. Although frequently remaining benign, a significant proportion exhibits malignant progression. Unfortunately, there are presently no accurate prognosticators for assessing cancer risk in individuals with IPMN. Moreover, the fundamental mechanisms differentiating PanIN and IPMN remain largely obscure, as do those that distinguish IPMN subtypes. Recent studies, however, have identified distinct genetic profiles between PanIN and IPMN, providing a framework to better understand the diversity of the precursors for PDA. Here, we review the clinical, biological, and genetic properties of IPMN and discuss various models for progression of these tumors to invasive PDA.
胰腺导管腺癌(PDA)是全球最致命的癌症之一,与两种主要类型的形态学上不同的癌前病变相关——胰腺上皮内瘤变(PanIN)和导管内乳头状黏液性肿瘤(IPMN)。尽管PanIN向浸润性癌的进展已得到充分表征,但仍迫切需要了解IPMN的生物学特性,IPMN是影像学上可检测到的较大的囊性肿瘤。IPMN包括多种具有异质性组织病理学和临床特征的亚型。尽管通常保持良性,但相当一部分会出现恶性进展。不幸的是,目前尚无准确的预后指标来评估IPMN患者的癌症风险。此外,区分PanIN和IPMN的基本机制以及区分IPMN亚型的机制在很大程度上仍不清楚。然而,最近的研究已经确定了PanIN和IPMN之间不同的基因谱,为更好地理解PDA癌前病变的多样性提供了一个框架。在这里,我们综述了IPMN的临床、生物学和遗传学特性,并讨论了这些肿瘤进展为浸润性PDA的各种模型。